Efficacy and safety of Shexiang Baoxin Pill combined with Baduanjin in the treatment of acute myocardial infarction: A prospective randomized study.

BACKGROUND

To evaluate the efficacy and safety of the Shexiang Baoxin Pill (SBP) combined with Baduanjin exercise in the treatment of patients with acute myocardial infarction (AMI).

METHODS

A total of 150 AMI patients who underwent percutaneous coronary intervention (PCI) were randomly assigned to 3 groups: Group A received conventional therapy combined with SBP and Baduanjin, Group B received conventional therapy with Baduanjin, and Group C received only conventional therapy. The study was conducted over 6 months, with primary outcomes measured using left ventricular ejection fraction (LVEF) for cardiac function, Hamilton Anxiety Scale (HAMA) for anxiety, Hamilton Depression Rating Scale (HAMD) for depression, and Myocardial Infarction Dimensional Assessment Scale (MIDAS) for quality of life. Safety was assessed by monitoring the incidence of adverse events.

RESULTS

Cardiac function significantly improved in all groups, with the most pronounced improvement observed in Group A (LVEF increased from 50.09% to 56.10%, P < .001). Group A also showed significant reductions in anxiety and depression scores (HAMA: from 18.30 to 10.07; HAMD: from 20.98 to 11.53, P < .05) and a substantial enhancement in quality of life (MIDAS: from 85.86 to 51.52, P < .05). No severe adverse events were reported.

CONCLUSION

The integrative approach of SBP and Baduanjin with conventional therapy significantly improved cardiac function, mental health, and quality of life in patients with AMI, offering a safe and effective adjunct to conventional care.